Testosterone Therapy

Federal Testosterone Therapy Lawsuits Top 3,000

3000 cases in testosterone therapy lawsuitsAccording to recent data from the U.S. Judicial Panel on Multidistrict Litigation, the number of testosterone therapy lawsuits pending in federal court has climbed to 3,238. The Illinois multidistrict litigation, established in June 2014, initially included just eight testosterone lawsuits.

Popular Low-T drugs like AndroGel, Axiron, and Testim are approved by the U.S. Food and Drug Administration (FDA) for use in men whose testosterone is low due to a medical ...

continue reading...

Judge Refuses to Drop AndroGel Co-Manufacturer from Testosterone MDL

judge refuses to drop androgen manufacturer from testosterone therapy lawsuitJudge Matthew Kennelly of the U.S. District Court for the District of Northern Illinois has denied Belgian company Besins Healthcare’s motion to dismiss itself from a multidistrict testosterone litigation, the Cook County Record reports. Along with AbbVie, Besins is responsible for the manufacture of AndroGel, one of the leading brands of testosterone therapy that have been targeted in a massive multi-state litigation.

Testosterone replacement therapy is ...

continue reading...

Endocrinology Groups Echo FDA Call for More Research on Testosterone Therapy Risks

endocrinologist group calls for testosterone therapy researchThe American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) recently issued a joint position statement on the cardiovascular risks of testosterone therapy. In the statement, the two endocrinology groups questioned the FDA’s recommended method for determining whether a patient requires testosterone therapy and call for more research on the health risks posed by Low-T products.

The FDA has indicated that testosterone therapy is approved ...

continue reading...

AbbVie Unhappy with Testosterone MDL Bellwether Trial Selection

abbvie not happy with bellwether trail selectionAbbVie, maker of the popular testosterone therapy product AndroGel, has expressed dissatisfaction with the federal court’s bellwether trial selection process, Forbes reports. The U.S. District Court for the Northern District of Illinois has chosen AbbVie to defend in the first MDL testosterone lawsuit to go to trial. AbbVie, a defendant in the fast-growing Illinois testosterone therapy MDL, has been instructed to select 32 potential cases to be prepared for bellwether ...

continue reading...

Testosterone Therapy Lawsuits Not Letting Up as South Carolina Claim Joins MDL

more testosterone therapy lawsuits join multidistrict litigationThe most recent report from the U.S. Judicial Panel on Multidistrict Litigation shows 2,231 testosterone lawsuits included in the Illinois MDL —and there’s no sign that the flood of lawsuits will let up any time soon. According to the Public Access to Court Electronic Records (PACER) database, over 40 new testosterone lawsuits were filed in the last week alone. A testosterone lawsuit filed last month by a South Carolina couple ...

continue reading...

New Testosterone Study Shows Mixed Results

Another pharma-funded testosterone therapy study has been published, this time in the Journal of the American Medical Association. The authors, two of whom worked with or profited from big-name testosterone therapy manufacturers, found that men who took testosterone did not show any significant difference in risk of atherosclerosis; at the same time, the study also revealed these men experienced no sexual or health-related improvement in quality of life. As noted by the researchers, the ...

continue reading...
Page 2 of 7 12345...»